Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058001 | 0.89 | KMT2A (0.35) | KMT2AMAP2K1BRD4TSHRCYP1A2 | |
| SCHEMBL31517932 | 0.81 | CYP2D6 (0.38) | KMT2AKDM4EHSD17B10 | |
| SCHEMBL7782098 | 0.81 | CYP2D6 (0.38) | KMT2AKDM4EHSD17B10 | |
| SCHEMBL2568105 | 0.78 | MCL1 (0.32) | — | |
| SCHEMBL29277043 | 0.77 | — | — | |
| SCHEMBL31378653 | 0.70 | CYP1A2 (0.34) | KMT2ABRD4CYP1A2HIF1A | |
| SCHEMBL2710718 | 0.70 | MAP2K1 (0.33) | KMT2AMAP2K1BRD4CYP1A2HIF1A | |
| SCHEMBL11799388 | 0.69 | CYP1A2 (0.37) | KMT2AMAP2K1BRD4CYP1A2HIF1A | |
| SCHEMBL9510438 | 0.69 | KDM4E (0.39) | KMT2AKDM4EHSD17B10 | |
| SCHEMBL2761099 | 0.69 | BRD4 (0.39) | KMT2ABRD4CYP1A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025092985-A1 | PHOSPHODIESTERASE 4B INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 合肥医工医药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| CN-119306709-A | Synthesis method of compound containing oxo-pyrido alicyclic heterocycle or alicyclic structure and novel intermediate | 成都思倍博医药科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-117247394-A | Nitrogen-containing heterocycles as PDE4B inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| US-4025630-A | Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication | ABBOTT LABORATORIES (US) | 1977-05-24 | — | — | US | disclosed |
| US-3987190-A | Method of treating hypertension with, and compositions useful therein containing, a 4H-thieno[2,3-c][1]benzopyran or a 3H,5H-thiopyrano[2,3-c][1] | SHARPS ASSOCIATES (US) | 1976-10-19 | — | — | US | disclosed |
| US-3972880-A | TRANQUILIZER | SHARPS ASSOCIATES (US) | 1976-08-03 | — | — | US | disclosed |
| US-3960871-A | ANTIDEPRESSANT, ANALGESICS, ANTICONVULSANT ANTI-ANXIETY ACTIVITY | SHARPS ASSOCIATES (US) | 1976-06-01 | — | — | US | disclosed |
| US-3940421-A | Intermediates for the preparation of thienobenzopyrans and thiopyranobenzopyrans | ARTHUR D. LITTLE, INC. (US) | 1976-02-24 | — | — | US | disclosed |
| US-3934024-A | 1,2-DIHYDRO-5,5-DIMETHYL-10-HYDROXY-8-(3-METHYL-2-OCTYL)-3H,5H -THIOPYRANO(2,3-C)(1)BENZOPYRAN) | SHARPS ASSOCIATES (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 3408/4885MAP2K1 2708/4885KDM4E 1574/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 3408/4885MAP2K1 2708/4885KDM4E 1574/4885 |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 3408/4885MAP2K1 2708/4885KDM4E 1574/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | KMT2A 1686/4885MAP2K1 3263/4885KDM4E 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.